XXXX registry in Japan from 2008 to 2013.

@entity1 @entity5 @entity1126 @entity3 @entity1086 @entity1125
PURPOSE: The present study analyzed @entity1125 @entity1 registered from 2008 to 2013 in Japan and evaluated the outcomes of @entity1125 . METHODS: A total of 18,606 @entity1 were registered from 2008 to 2013. Cases were analyzed with regard to @entity1 survival according to contiguous extent of the @entity5 ( @entity5 ), node @entity3 , and @entity5 stage using the 3rd English edition of the Japanese General Rules for @entity1125 . RESULTS: Five-year survival rates were 39.8% for @entity1086 , 24.2% for perihilar @entity1126 , 39.1% for @entity1126 , and 61.3% for ampullary region @entity5 . Significant differences were observed between newly introduced subdivisions in the new Japanese classification for all tumoral sites except @entity1086 . The survival rate in @entity1 with #13a @entity3 was significantly higher than in @entity1 with distant lymph node @entity3 . CONCLUSIONS: The new Japanese classification adopted the 7th edition of staging system developed by the Union for International @entity5 Control staging system. However, numerous aspects of these classification systems remain unvalidated. The present analysis demonstrated the significance of a proportion of @entity5 factor subdivisions and classifications of regional lymph nodes in cases of @entity1086 in the new Japanese classification. This article is protected by copyright. All rights reserved.
